cenegermin
{{Short description|Pharmaceutical drug}}
{{Use dmy dates|date=October 2024}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Infobox drug
| image =
| width =
| alt =
| pronounce =
| tradename = Oxervate
| Drugs.com = {{drugs.com|monograph|cenegermin-bkbj}}
| MedlinePlus = a619001
| DailyMedID = Cenegermin
| pregnancy_AU = B3
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration = Ophthalmic
| class =
| ATC_prefix = S01
| ATC_suffix = XA24
| ATC_supplemental =
| legal_AU = S4
| legal_AU_comment = {{cite web | title=AusPAR: Cenegermin | website=Therapeutic Goods Administration (TGA) | date=23 December 2019 | url=https://www.tga.gov.au/auspar/auspar-cenegermin-rbe | access-date=26 August 2020 | archive-date=1 November 2021 | archive-url=https://web.archive.org/web/20211101215946/https://www.tga.gov.au/auspar/auspar-cenegermin-rbe | url-status=dead }}{{cite web | title=Oxervate APMDS | website=Therapeutic Goods Administration (TGA) | date=26 May 2022 | url=https://www.tga.gov.au/resources/auspmd/oxervate | access-date=10 March 2024}}
| legal_BR =
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment = / Schedule D{{cite web | title=Summary Basis of Decision (SBD) for Oxervate | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00439&lang=en | access-date=29 May 2022}}
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US = Rx-only
| legal_EU = Rx-only
| legal_UN =
| legal_UN_comment =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
| CAS_number = 1772578-74-1
| CAS_supplemental =
| PubChem =
| IUPHAR_ligand =
| DrugBank = DB13926
| ChemSpiderID = None
| UNII = B6E7K36KT8
| KEGG = D11028
| ChEBI =
| ChEMBL =
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = Recombinant human nerve growth factor; rhNGF, cenegermin-bkbj
| IUPAC_name =
| C=583 | H=908 | N=166 | O=173 | S=8
| SMILES =
| StdInChI_Ref =
| StdInChI =
| StdInChI_comment =
| StdInChIKey_Ref =
| StdInChIKey =
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor. Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR).
The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye.
It was approved for medical use in the European Union in July 2017,{{cite web | title=Oxervate EPAR | website=European Medicines Agency (EMA) | date=25 July 2017 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/oxervate | access-date=25 August 2020}} and in the United States in 2018. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.{{cite report | title=New Drug Therapy Approvals 2018 | website=U.S. Food and Drug Administration (FDA) | date=January 2019 | url=https://www.fda.gov/media/120357/download | archive-url=https://web.archive.org/web/20190826114431/https://www.fda.gov/media/120357/download | url-status=dead | archive-date=26 August 2019 | format=PDF | access-date=16 September 2020}}
Medical uses
Cenegermin is indicated for the treatment of neurotrophic keratitis.
Society and culture
= Names =
Cenegermin is the international nonproprietary name.{{cite journal | vauthors=((World Health Organization)) | year=2017 | title=International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77 | journal=WHO Drug Information | volume=31 | issue=1 | page=76 | hdl=10665/330984 | hdl-access=free | author-link = World Health Organization }} It is also known as human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer) produced in Escherichia coli.
References
{{Reflist}}
Further reading
- {{cite journal | vauthors = Deeks ED, Lamb YN | title = Cenegermin: A Review in Neurotrophic Keratitis | journal = Drugs | volume = 80 | issue = 5 | pages = 489–494 | date = April 2020 | pmid = 32185680 | doi = 10.1007/s40265-020-01289-w }}
- {{cite journal | vauthors = Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, Foster CS, Affeldt J, Seedor JA, Afshari NA, Chao W, Allegretti M, Mantelli F, Dana R | title = Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial | journal = Ophthalmology | volume = 127 | issue = 1 | pages = 14–26 | date = January 2020 | pmid = 31585826 | doi = 10.1016/j.ophtha.2019.08.020 | title-link = doi | doi-access = free }}
- {{cite journal |vauthors=Sheha H, Tighe S, Hashem O, Hayashida Y |title=Update On Cenegermin Eye Drops In The Treatment Of Neurotrophic Keratitis |journal=Clin Ophthalmol |volume=13 |pages=1973–1980 |date=October 2019 |pmid=31631965 |pmc=6789413 |doi=10.2147/OPTH.S185184 |doi-access=free |title-link=doi }}
{{Growth factor receptor modulators}}
{{Portal bar | Medicine}}
{{Authority control}}